Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.